Chemistry Reference
In-Depth Information
Alternative routes for the in vivo administration of boronated porphyrin
derivatives have been investigated with the aim to increase permeability across
the BBB and tumor uptake. A very promising methodology is convection-enhanced
delivery (CED), which is able to deliver extremely high amounts of boron
(
ΚΌ
g/g) to intracerebral animal tumors, with very high tumor-to-normal
brain and tumor-to-blood boron ratios, and no systemic toxicity [
95
-
97
].
Among the porphyrin derivatives, boronated chlorins, corroles, bacteriochlorins,
and phthalocyanines can be used as dual BNCT and PDT sensitizers because of
their absorptions of near-IR light that penetrates deeper into human tissues. The
combination of the BNCT and PDT therapies could lead to higher efficacy of tumor
treatment via the targeting of different mechanisms of tumor cell destruction.
However, current clinical development of BNCT and investigation of the biological
properties of new boron delivery agents are slow for a variety of reasons, including
readily availability of adequate neutron sources and cost. Nevertheless, the outlook
for BNCT is bright since this binary therapy offers new hope for otherwise
untreatable cancers.
>
100
Acknowledgments
The support from the US National Institutes of Health (grant number R01 CA
098902) is acknowledged.
References
1. Hawthorne MF (1993) The role of chemistry in the development of boron neutron capture
therapy of cancer. Angew Chem Int Ed 32:950-984
2. Soloway AH, Tjarks W, Barnum BA et al (1998) The chemistry of neutron capture therapy.
Chem Rev 98:1515-1562
3. Barth RF, Coderre JA, Vicente MGH (2005) Boron neutron capture therapy of cancer: current
status and future prospects. Clin Cancer Res 11:3987-4002
4. Barth RF, Vicente MGH, Harling OK et al (2012) Current status of boron neutron capture
therapy of high grade gliomas and recurrent head and neck cancer. Radiat Oncol 7:146
5. Hopewell JW, Gorlia T, Pellettieri L et al (2011) Boron neutron capture therapy for newly
diagnosed glioblastoma multiforme: an assessment of clinical potential. Appl Radiat Isot
69:1737-1740
6. Kawabata S, Miyatake S, Hiramatsu R et al (2011) Phase II clinical study of boron neutron
capture therapy combined with X-ray radiotherapy/temozolomide in patients with newly
diagnosed glioblastoma multiforme - study design and current status report. Appl Radiat
Isot 69:1796-1799
7. Kankaanranta L, Seppala T, Koivunoro H et al (2011)
L
-Boronophenylalanine-mediated boron
neutron capture therapy for malignant glioma progressing after external beam radiation
therapy: a phase I study. Int J Radiat Oncol Biol Phys 80:369-376
8. Yamamoto T, Nakai K, Nariai T et al (2011) The status of Tsukuba BNCT trial: BPA-based
boron neutron capture therapy combined with X-ray irradiation. Appl Radiat Isot 69:
1817-1818
9. Kankaanranta L, Seppala T, Koivunoro H et al (2012) Boron neutron capture therapy in the
treatment of locally recurred head-and-neck cancer: final analysis of a phase I/II trial. Int J
Radiat Oncol Biol Phys 82:e67-e75
